CGTN
A total of 832 counties, 128,000 villages and nearly 100 million people were living in poverty. This was the reality that China had to face. The task of providing support to them all wasn't easy, and making sure that everyone receives the exact help they needed was even harder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005505/en/
"Who were these people and where were they located? If you are intent on leaving no one behind, then you have to locate each and every one of them and tailor relief measures accordingly," said Lin Wanlong, professor of economics and management at China Agriculture University.
In November 2013, during an inspection tour of central China's Hunan, Chinese President Xi Jinping first raised the concept of "targeted poverty alleviation." To crystalize it, he said one should "seek truth from facts, tailor measures to suit local conditions, give targeted guidance, and be meticulous about the work." These points have become the guiding principle in China's fight against poverty.
The first step of the targeted poverty alleviation campaign is to locate poverty through accurate identification, which means specifying survey data by matching it with individuals and households. Are there any better-off families in impoverished counties? Are there any poor households in rich townships? How does one differentiate whether a family really needs help? These were the first challenges that the campaign had to overcome.
"When I was just assigned to the township, I was informed that there were over 2,300 households and about 8,000 people living in poverty. But nobody knew who exactly they were," said Zhu Shengjiang, head of Yeping Town in Jiangxi Province's Ruijin City.
In a township of over 70,000 people, a poor population of over 8,000 was scattered among 399 villager groups. Zhu and his colleagues had to go door-to-door and look meticulously into their respective family conditions. Once poverty is identified, they would set up file for the households and log their information onto system.
The ultimate aim of poverty alleviation is to ensure people don't have to worry about food and clothing and have access to compulsory education, basic medical services and safe housing. Commonly known as the "two assurances and three guarantees," these are the key indicators for poverty relief officials to identify who exactly needs help.
"In each household, we look at things like whether there is sufficient working capacity, whether the child is receiving education and whether all family members are healthy. If the answer is no in all these categories, then we have found a household that really needs help," said Zeng Nenggui, director of poverty relief office in Ruijin City.
The launching of a national digital database has enabled data to cover each and every registered village, household and individual, which not only ensures the accuracy of poverty identification but helps nail down the causes of poverty for those who are in the system.
"These households are like a benchmark. What we do is to analyze their conditions and come up with tailor-made measures to lift them out of poverty," said Lu Chunsheng, director of the Information Center of the National Bureau of Rural Development. "For example, if a family remains poor because they couldn't receive proper education, our relief measures should include granting student loans and subsidies. If poverty is caused by a family member's poor health conditions, we then should provide them with sufficient healthcare."
Prescribing the right remedy is the key. Under President Xi's guidance, the targeted poverty alleviation campaign has five key measures.
Development & Production
All 832 registered counties have formulated industrial plans to fight against poverty, with over 300,000 industrial bases in farming, planting and processing being constructed on site.
Relocation
More than 96 million registered people have moved into over 2.66 million newly constructed houses, all equipped with water, electricity, gas and internet. Transportation is convenient with better roads built.
Ecological compensation
Over 1.1 million registered people have been employed as ecological forest rangers, directly lifting a total of 3 million out of poverty.
Education
About 200,000 students who dropped out of school due to poverty have now returned to school. More than 8 million students from poor families who failed to continue their studies or get employed after finishing high school have received vocational education for free.
Social security
Since 2016, a total of 19.36 million registered people have been included in the subsistence allowance, support and relief system.
To ensure that poverty is truly lifted, the strictest assessment system has been put in place. For each county to declare it has officially left poverty behind, it has to be thoroughly assessed by a third-party inspection team.
"We have never encountered such rigorous measures," said Zhang Shibin, former director of the poverty alleviation office of Yunnan Province's Luquan Yi and Miao Autonomous County. " During the third-party inspection, village officials are not even allowed to follow these teams into the village."
The targeted poverty alleviation campaign has perfectly embodied China's practical and down-to-earth approach in battling poverty, opening up a path that accommodates the country's realities while reflecting unique Chinese characteristics.
Original article: here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
